Loading...
Docoh

Aptevo Therapeutics (APVO)

Filed: 7 Jun 22, 4:46pm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  June 7, 2022

 

APTEVO THERAPEUTICS INC.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

001-37746

81-1567056

(State or Other Juris-

diction of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

2401 4th Avenue, Suite 1050

Seattle, Washington

98121

(Address of Principal Executive Offices)

(Zip Code)

 

Registrant’s telephone number, including area code: (206) 838-0500

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.001 par value

 

APVO

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 


 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On June 7, 2022, Aptevo Therapeutics Inc. (the “Company”) held its 2022 Annual Meeting of Stockholders (the “Annual Meeting”), at which a quorum was present.  Stockholders considered five proposals outlined below, each of which is described in more detail in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 27, 2022 (the “Proxy Statement”).  The final voting results with respect to each of the proposals acted upon at the 2022 Annual Meeting are set forth below.

Proposal 1: Election of Directors

The following two nominees, each of whom were named in the Proxy Statement, were elected to serve on the Board of Directors to hold office until the 2025 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, based on the following votes:  All director nominees were elected based on the following votes:

 

  

FOR

  

WITHHELD

  

BROKER
NON-VOTES

Marvin L. White

  

1,407,493

  

211,775

  

1,585,619

John E. Niederhuber, M.D.

  

1,327,090

  

292,178

  

1,585,619

 

 

Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm for 2022

 

The appointment of Moss Adams LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2022 was approved based on the following votes:

FOR

 

AGAINST

 

ABSTAIN

 

3,139,114

 

27,114

 

38,659

 

 

Proposal 3: Approval of Aptevo Therapeutics Inc. 2018 Stock Incentive Plan (as Amended and Restated)

 

The Aptevo Therapeutics Inc. 2018 Stock Incentive Plan was approved based on the following votes:

 

FOR

 

AGAINST

 

ABSTAIN

 

BROKER

NON-VOTES

1,519,205

 

 

 

91,919

 

8,144

 

1,585,619

 

Proposal 4: Approval, on a non-binding advisory basis, the compensation of the Company’s named executive officer compensation as disclosed in the Proxy Statement  

 

The non-binding advisory proposal was approved based on the following votes:

FOR

 

AGAINST

 

ABSTAIN

 

BROKER

NON-VOTES

1,477,018

 

130,421

 

11,829

 

1,585,619

 

 

Proposal 5: Approval, on a non-binding advisory basis, the frequency of future advisory votes to approve named executive officer compensation

 

A one-year interval as the frequency with which stockholders are to be provided an advisory vote on executive compensation was approved on an advisory (non-binding) basis, based on the following votes:

 

1 YEAR

 

2 YEARS

 

3 YEARS

 

ABSTAIN

 

1,317,290

 

16,285

 

20,889

 

264,804

 

 

 

 

 

 

 


 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

APTEVO THERAPEUTICS INC.

 

 

 

Date:  June 7, 2022

By:

/s/ Marvin L. White

 

 

Marvin L. White

President and Chief Executive Officer